Evidence map›Paper›PMID 24482739›Full record

ArticleAmerican journal of cancer research2014

Biomarkers and endosalpingiosis in the ovarian and tubal microenvironment of women at high-risk for pelvic serous carcinoma.

Christine Gruessner, Angelika Gruessner, Katherine Glaser, Nisreen Abushahin, Cynthia Laughren, Wenxin Zheng, Setsuko K Chambers

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Christine GruessnerCollege of Medicine, University of Arizona Tucson, AZ, USA.
Angelika GruessnerMel and Enid Zuckerman College of Public Health, University of Arizona Tucson, AZ, USA.
Katherine GlaserCollege of Medicine, University of Arizona Tucson, AZ, USA ; Department of Obstetrics and Gynecology, University of Arizona Tucson, AZ, USA.
Nisreen AbushahinDepartment of Pathology, University of Jordan Amman, Jordan ; Department of Pathology, University of Arizona Tucson, AZ, USA.
Cynthia LaughrenUniversity of Arizona Cancer Center Tucson, AZ, USA.
Wenxin ZhengCollege of Medicine, University of Arizona Tucson, AZ, USA ; University of Arizona Cancer Center Tucson, AZ, USA ; Department of Pathology, University of Arizona Tucson, AZ, USA.
Setsuko K ChambersCollege of Medicine, University of Arizona Tucson, AZ, USA ; Department of Obstetrics and Gynecology, University of Arizona Tucson, AZ, USA ; University of Arizona Cancer Center Tucson, AZ, USA.
University of Arizona · USUniversity of Jordan · JO

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
SHORT-TERM TRAINING STUDENTS IN HEALTH PROFESSIONAL SCHOT35HL007479 · NHLBI · UNIVERSITY OF ARIZONA · PI GEOFFREY C GURTNER, JAMES Kuang-Jan LIAO · 1985 to 2026
$4.4M
NCI NIH HHS P30 CA023074NHLBI NIH HHS T35 HL007479
6 · The paper itself

Abstract

introductionBRCA mutations increase the risk for development of high-grade pelvic serous carcinomas. Tissue biomarkers distinguishing women at high-risk (HR) for ovarian cancer from those at low-risk (LR) may provide insights into tumor initiation pathways.

methodsA prospective study of 47 HR women (40% BRCA carriers) undergoing risk-reducing salpingo-oophorectomy and 48 LR controls undergoing salpingo-oophorectomy was performed. Ovarian/tubal tissues were harvested. Immunohistochemical analysis of candidate proteins CSF-1, CSF-1R, ErbB4 is presented, with scores separately analyzed in epithelium and stroma, in ampulla, fimbria, ovary, and ovarian endosalpingiosis (ES). Comparison was performed between HR and LR groups.

resultsElevated levels of CSF-1 (p=0.005) or ErbB4 (p=0.005) in the ovarian epithelium, or ErbB4 (p=0.005) in the ovarian stroma, were significantly associated with both the HR status and carrying a BRCA mutation, as was nuclear ErbB4 staining. Ovarian ES, an entity which likely derives from the tubal mucosal epithelium, was also associated with HR (p=0.038) and BRCA mutation status (p=0.011). Among the BRCA carriers only, markers also found association when present in the tube as well as in ovarian ES (p < 0.05). ROCs were generated including in the regression model both CSF-1 and ErbB4 expression levels. A model including CSF-1 in ovarian epithelium, ErbB4 in ovarian stroma, and younger age achieves AUC=0.87 (73% sensitivity, 93% specificity) of detection of the HR status. In BRCA carriers, CSF-1 in ovarian epithelium alone achieves AUC=0.85.

conclusionsOur data suggest that elevated levels of CSF-1/ErbB4 in the adnexae correlate with HR/BRCA carrier status. CSF-1/CSF-1R signaling is active in ovarian cancer progression; our data suggests a role in its initiation. ErbB4, in particular nuclear ErbB4, may have a role in tumor initiation as well. Ovarian ES, an entity which may represent a latent precursor to low-grade pelvic serous carcinomas, was surprisingly associated with both HR status and the BRCA carrier cohort. In line with these findings, both ErbB4 and CSF-1R expression in ovarian ES correlated with carrying a BRCA mutation. This analysis, which needs to be validated, indirectly suggests a potential link between ovarian ES and the development of pelvic serous carcinoma in women who are BRCA mutation carriers.

Indexed as

CSF-1endosalpingiosisErbB4high-risk

Identifiers

PMID24482739
PMCPMC3902233
OpenAlexW114702829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.